{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Recurrence&page=6",
    "query": {
      "condition": "Bladder Cancer Recurrence",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 180,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Recurrence&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Recurrence&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T22:55:41.743Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00004095",
      "title": "Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 38,
      "start_date": "1999-08",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2017-04-18",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004095"
    },
    {
      "nct_id": "NCT00030498",
      "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Mixed Glioma",
        "Adult Myxopapillary Ependymoma",
        "Adult Oligodendroglioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Primary Hepatocellular Carcinoma",
        "Adult Subependymoma",
        "Advanced Adult Primary Liver Cancer",
        "Advanced Malignant Mesothelioma",
        "Male Breast Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adult Brain Tumor",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Bladder Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Esophageal Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage II Esophageal Cancer",
        "Stage II Pancreatic Cancer",
        "Stage III Esophageal Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Anal Cancer",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Bladder Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esophageal Cancer",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2001-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030498"
    },
    {
      "nct_id": "NCT00021099",
      "title": "Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Distal Urethral Cancer",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Proximal Urethral Cancer",
        "Recurrent Bladder Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Stage III Bladder Cancer",
        "Stage IV Bladder Cancer",
        "Transitional Cell Carcinoma of the Bladder",
        "Urethral Cancer Associated With Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2001-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021099"
    },
    {
      "nct_id": "NCT00020579",
      "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2001-03",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020579"
    },
    {
      "nct_id": "NCT00397488",
      "title": "Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 78,
      "start_date": "2006-09",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00397488"
    },
    {
      "nct_id": "NCT00022633",
      "title": "S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 65,
      "start_date": "2001-07",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-11",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 92,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valdosta",
          "state": "Georgia"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022633"
    },
    {
      "nct_id": "NCT00072137",
      "title": "Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Bladder Urothelial Carcinoma",
        "Recurrent Bladder Carcinoma",
        "Stage I Bladder Cancer",
        "Stage II Bladder Cancer",
        "Stage III Bladder Cancer",
        "Stage IV Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Recombinant Fowlpox-TRICOM Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Fowlpox GM-CSF Vaccine Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 21,
      "start_date": "2003-10",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072137"
    },
    {
      "nct_id": "NCT01846520",
      "title": "Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Subject",
        "Localized Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Recurrent Bladder Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Recurrent Uterine Sarcoma",
        "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Stage II Bladder Cancer",
        "Stage II Renal Cell Cancer",
        "Stage II Urethral Cancer",
        "Stage IIA Cervical Cancer",
        "Stage IIA Colon Cancer",
        "Stage IIA Gastric Cancer",
        "Stage IIA Ovarian Epithelial Cancer",
        "Stage IIA Ovarian Germ Cell Tumor",
        "Stage IIA Pancreatic Cancer",
        "Stage IIA Rectal Cancer",
        "Stage IIA Uterine Sarcoma",
        "Stage IIB Cervical Cancer",
        "Stage IIB Colon Cancer",
        "Stage IIB Gastric Cancer",
        "Stage IIB Ovarian Epithelial Cancer",
        "Stage IIB Ovarian Germ Cell Tumor",
        "Stage IIB Pancreatic Cancer",
        "Stage IIB Rectal Cancer",
        "Stage IIB Uterine Sarcoma",
        "Stage IIC Colon Cancer",
        "Stage IIC Ovarian Epithelial Cancer",
        "Stage IIC Ovarian Germ Cell Tumor",
        "Stage IIC Rectal Cancer",
        "Stage III Bladder Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Urethral Cancer",
        "Stage IIIA Cervical Cancer",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIA Ovarian Epithelial Cancer",
        "Stage IIIA Ovarian Germ Cell Tumor",
        "Stage IIIA Rectal Cancer",
        "Stage IIIA Uterine Sarcoma",
        "Stage IIIB Cervical Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIB Ovarian Epithelial Cancer",
        "Stage IIIB Ovarian Germ Cell Tumor",
        "Stage IIIB Rectal Cancer",
        "Stage IIIB Uterine Sarcoma",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IIIC Ovarian Epithelial Cancer",
        "Stage IIIC Ovarian Germ Cell Tumor",
        "Stage IIIC Rectal Cancer",
        "Stage IIIC Uterine Sarcoma",
        "Stage IV Bladder Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Pancreatic Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Urethral Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVA Uterine Sarcoma",
        "Stage IVB Cervical Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer",
        "Stage IVB Uterine Sarcoma",
        "Ureter Cancer",
        "Stage IIA Lung Carcinoma",
        "Stage IIB Lung Carcinoma",
        "Stage IIIA Lung Carcinoma",
        "Stage IIIB Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "telephone-based intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2013-10-29",
      "completion_date": "2019-05-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846520"
    },
    {
      "nct_id": "NCT00118040",
      "title": "Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Bladder Carcinoma",
        "Stage I Bladder Cancer AJCC v6 and v7",
        "Stage II Bladder Cancer AJCC v6 and v7",
        "Stage III Bladder Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Genistein",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2005-06-24",
      "completion_date": "2010-08-15",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Laguna Hills, California • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00118040"
    },
    {
      "nct_id": "NCT03933826",
      "title": "CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Cancer of the Bladder, Recurrent",
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2019-07-09",
      "completion_date": "2029-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-30T22:55:41.743Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03933826"
    }
  ]
}